HUTCHMED [NASDAQ: HCM] Sign Agreement with NHSA for ELUNATE and SULANDA

HUTCHMED (China) Limited [NASDAQ: HCM] revealed that it has inked an agreement with the China National Healthcare Security Administration (NHSA) for the continued inclusion of ELUNATE and the addition of SULANDA in the National Reimbursement Drug List (NRDL) in China. The company disclosed that after the successful negotiation in 2021, from January 1, 2022, onward the updated NRDL will continue to include ELUNATE and will now include SULANDA.

Over the past few years, the government in China has put great emphasis on enhancing the public accessibility of drug use. The NHSA frequently organizes a broad network of experts in medicine, pharmacology, and Pharmacoeconomics to recognize advanced drugs to be deemed for addition in the NRDL.

HUTCHMED appreciates the addition of SULANDA into the NRDL, along with the renewal of ELUNATE. The NRDL has enabled novel therapies to obtain broad reach across the country for diseases with large patient populations. Presently, there are around 13,000 newly discovered NSCLC victims with MET exon 14 skipping alterations each year in China.

About ELUNATE

ELUNATE has first gained inclusion in the NRDL on January 1, 2020, for the cure of metastatic colorectal cancer (CRC). Presently, CRC was the third most detected form of cancer by incidence in China in 2020, with approximately 450,000 to 550,000 new cases each year.

About SULANDA

SULANDA has gained inclusion in China for the cure of advanced non-pancreatic neuroendocrine tumors (NETs) in December 2020 and for advanced pancreatic NETs in June 2021. In China, there were approximately 71,300 newly diagnosed NET patients in 2020, with possibly up to 300,000 patients living with the disease.